Inefficacy of propranolol in attenuation of drug‐induced parkinsonian tremor
Identifieur interne : 003319 ( Istex/Curation ); précédent : 003318; suivant : 003320Inefficacy of propranolol in attenuation of drug‐induced parkinsonian tremor
Auteurs : Metzer [États-Unis] ; Paige [États-Unis] ; Joseph E. O. Newton [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1993.
English descriptors
- KwdEn :
Abstract
We investigated the tremolytic effect of long‐acting propranolol (propranolol‐LA) in six subjects with drug‐induced parkinsonism (DIP), using a double‐blind, placebo‐controlled, crossover experimental design. Subjects received propranolol‐LA for 2 weeks and placebo for 2 weeks, with no change in neuroleptic treatment. Tremor frequency and amplitude were objectively quantified at the end of each 2‐week period by computerized tremorgram recording. There were no significant differences in attenuation of DIP tremor by propranolol‐ LA and placebo. Previous investigations reported in the literature have found propranolol to attenuate the tremor of idiopathic parkinsonism (IPD). It is expected that DIP and IPD tremor would respond similarly to propranolol if a solely peripheral or spinal cord tremolytic action were operative. A possible differential attenuation of IPD tremor and DIP tremor provides support for the concept of a higher central tremolytic mechanism of β‐adrenergic receptor‐blocking drugs.
Url:
DOI: 10.1002/mds.870080108
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003319
Links to Exploration step
ISTEX:BB8B6D5AE5770F4C31398E8358BFF8384112476ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inefficacy of propranolol in attenuation of drug‐induced parkinsonian tremor</title><author><name sortKey="Metzer" sort="Metzer" uniqKey="Metzer" last="Metzer">Metzer</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Psychiatry, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas</wicri:regionArea></affiliation></author><author><name sortKey="Paige" sort="Paige" uniqKey="Paige" last="Paige">Paige</name><affiliation wicri:level="1"><mods:affiliation>Department of Psychiatry, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas</wicri:regionArea></affiliation><affiliation wicri:level="2"><mods:affiliation>Current Address: Creighton‐Nebraska Combined Department of Psychiatry in Omaha, NE</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Nebraska</region></placeName><wicri:cityArea>Current Address: Creighton‐Nebraska Combined Department of Psychiatry in Omaha</wicri:cityArea></affiliation></author><author><name sortKey="Newton, Joseph E O" sort="Newton, Joseph E O" uniqKey="Newton J" first="Joseph E. O." last="Newton">Joseph E. O. Newton</name><affiliation wicri:level="1"><mods:affiliation>Department of Psychiatry, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BB8B6D5AE5770F4C31398E8358BFF8384112476A</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1002/mds.870080108</idno><idno type="url">https://api.istex.fr/document/BB8B6D5AE5770F4C31398E8358BFF8384112476A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003319</idno><idno type="wicri:Area/Istex/Curation">003319</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Inefficacy of propranolol in attenuation of drug‐induced parkinsonian tremor</title><author><name sortKey="Metzer" sort="Metzer" uniqKey="Metzer" last="Metzer">Metzer</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Psychiatry, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas</wicri:regionArea></affiliation></author><author><name sortKey="Paige" sort="Paige" uniqKey="Paige" last="Paige">Paige</name><affiliation wicri:level="1"><mods:affiliation>Department of Psychiatry, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas</wicri:regionArea></affiliation><affiliation wicri:level="2"><mods:affiliation>Current Address: Creighton‐Nebraska Combined Department of Psychiatry in Omaha, NE</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Nebraska</region></placeName><wicri:cityArea>Current Address: Creighton‐Nebraska Combined Department of Psychiatry in Omaha</wicri:cityArea></affiliation></author><author><name sortKey="Newton, Joseph E O" sort="Newton, Joseph E O" uniqKey="Newton J" first="Joseph E. O." last="Newton">Joseph E. O. Newton</name><affiliation wicri:level="1"><mods:affiliation>Department of Psychiatry, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry, University of Arkansas for Medical Science, and the Neurology and Psychiatry Services, McClellan Memorial Veterans Administration Medical Center, Little Rock, Arkansas</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1993">1993</date><biblScope unit="vol">8</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="43">43</biblScope><biblScope unit="page" to="46">46</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">BB8B6D5AE5770F4C31398E8358BFF8384112476A</idno><idno type="DOI">10.1002/mds.870080108</idno><idno type="ArticleID">MDS870080108</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Essential tremor</term><term>Parkinson's disease</term><term>Parkinsonism</term><term>Propranolol</term><term>Tremor</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We investigated the tremolytic effect of long‐acting propranolol (propranolol‐LA) in six subjects with drug‐induced parkinsonism (DIP), using a double‐blind, placebo‐controlled, crossover experimental design. Subjects received propranolol‐LA for 2 weeks and placebo for 2 weeks, with no change in neuroleptic treatment. Tremor frequency and amplitude were objectively quantified at the end of each 2‐week period by computerized tremorgram recording. There were no significant differences in attenuation of DIP tremor by propranolol‐ LA and placebo. Previous investigations reported in the literature have found propranolol to attenuate the tremor of idiopathic parkinsonism (IPD). It is expected that DIP and IPD tremor would respond similarly to propranolol if a solely peripheral or spinal cord tremolytic action were operative. A possible differential attenuation of IPD tremor and DIP tremor provides support for the concept of a higher central tremolytic mechanism of β‐adrenergic receptor‐blocking drugs.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003319 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 003319 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:BB8B6D5AE5770F4C31398E8358BFF8384112476A
|texte= Inefficacy of propranolol in attenuation of drug‐induced parkinsonian tremor
}}
| This area was generated with Dilib version V0.6.23. |  |